Neoadjuvant Chemotherapy with Sequential Methotrexate and 5-Fluorouracil Scheduling, Epirubicin and Cisplatin for Locally Advanced Bladder Cancer

Oncology ◽  
2002 ◽  
Vol 63 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Tsutomu Nishiyama ◽  
Toshiki Tanikawa ◽  
Yoshihiko Tomita ◽  
Kota Takahasi
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Bladder Cancer ◽  
Sequential Methotrexate

Neoadjuvant Chemotherapy Plus Cystectomy Compared With Cystectomy Alone for Locally Advanced Bladder Cancer

2021 ◽  
pp. 141-146
Author(s):  
Vikram M. Narayan
Keyword(s):  
Adverse Effect ◽  
Overall Survival ◽  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Randomized Study ◽  
Locally Advanced ◽  
Common Adverse Effect ◽  
Advanced Bladder Cancer ◽  
Muscle Invasive

This study summarizes a landmark study on the role of neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in patients with muscle-invasive bladder cancer. This randomized study of M-VAC plus cystectomy versus cystectomy alone suggested improved overall survival in patients receiving neoadjuvant therapy. Severe granulocytopenia was a common adverse effect in the chemotherapy group, but no deaths were attributed to chemotherapy.

P107 Neoadjuvant chemotherapy for locally advanced bladder cancer, does it really work?

2014 ◽  
Vol 13 (5) ◽  
pp. 150
Author(s):  
B. Özdemir ◽  
B. Akdoğan ◽  
M. Altan ◽  
B. Çıtamak ◽  
O. Kahraman ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Bladder Cancer

A pilot study of neoadjuvant chemotherapy with gemcitabine (GMZ) plus a platinum compound in locally advanced bladder cancer: Preliminary results.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e15142-e15142
Author(s):  
G. Nazzicone ◽  
G. Schinzari ◽  
M. Racioppi ◽  
A. Inno ◽  
A. Amoruso ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Pilot Study ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Platinum Compound ◽  
Preliminary Results ◽  
Advanced Bladder Cancer

Rapid organoid development, drug screening, and neoadjuvant chemotherapy response prediction for patients with locally advanced bladder cancer.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 543-543
Author(s):  
Samuel D. Kaffenberger ◽  
Jason Brown ◽  
Nathan Merrill ◽  
Kathryn Marchetti ◽  
Li Wei Bao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Rna Sequencing ◽  
Drug Screening ◽  
Drug Response ◽  
Locally Advanced ◽  
Response Prediction ◽  
Chemotherapy Response ◽  
A Value ◽  
Advanced Bladder Cancer

543 Background: Neoadjuvant chemotherapy prior to radical cystectomy (RC) for muscle-invasive urothelial carcinoma (UCCx) is the standard of care though the absolute survival benefit is small, and some patients progress during chemotherapy. While progress has been made in the prediction of sensitivity to platinum-based chemotherapies, providing more accurate, personalized, and clinically-relevant chemotherapy response prediction is an unmet need. We present our early and ongoing experience with rapid, organoid-based drug-screening. Methods: one gram of tumor was procured from patients undergoing TURBT or RC and divided between DNA/RNA sequencing, organoid drug-screening, and patient-derived xenografts. Tissue was dissociated, filtered, and resuspended in organoid media for serial passage and drug screening. Drugs were tested at “Cmax” concentration, which is the maximum plasma concentration in human trials so as to provide physiologic relevance. Results were normalized to control such that a value of 100 indicated no drug effect compared to control, and a value of 0 indicated complete response. Number of drugs screened was dependent upon tissue available, but was often 20-30. Results: 25 patients have undergone rapid organoid development and drug testing to date. Clinical correlations with chemotherapy response are ongoing. Drug response analyses were available 5-10 days following procedure. Select drug response data from the 9 most recent patient organoid samples are presented in the Table. DNA and RNA sequencing and PDX models are in progress. Conclusions: This platform allows for the rapid determination of neoadjuvant chemotherapy response and may further guide selection of therapeutic agents in patients with locally advanced bladder cancer.[Table: see text]

Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer

Oncology ◽  
2017 ◽  
Vol 93 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Dora Niedersüss-Beke ◽  
Thomas Puntus ◽  
Thomas Kunit ◽  
Birgit Grünberger ◽  
Michael Lamche ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Bladder Cancer

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

2003 ◽  
Vol 349 (9) ◽  
pp. 859-866 ◽  
Author(s):  
H. Barton Grossman ◽  
Ronald B. Natale ◽  
Catherine M. Tangen ◽  
V.O. Speights ◽  
Nicholas J. Vogelzang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Bladder Cancer
Sign in / Sign up

Export Citation Format

Share Document